Literature DB >> 16368266

Mechanism of action of memantine.

Jon W Johnson1, Shawn E Kotermanski.   

Abstract

Memantine is a clinically useful drug in many neurological disorders, including Alzheimer's disease. The principal mechanism of action of memantine is believed to be the blockade of current flow through channels of N-methyl-d-aspartate (NMDA) receptors--a glutamate receptor subfamily broadly involved in brain function. Surprisingly, other drugs that block NMDA receptor channels, such as ketamine, exhibit serious deleterious effects. The unusual therapeutic utility of memantine probably results from inhibitory mechanisms shared with ketamine, combined with actions specific to memantine. These potentially important differences between memantine and ketamine include effects on gating of blocked channels and binding of memantine to two sites on NMDA receptors. Because modulation of NMDA receptor activity can increase or decrease excitability of neuronal circuits, subtle differences in the mechanisms of action of NMDA receptor antagonists can strongly impact on their clinical effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16368266     DOI: 10.1016/j.coph.2005.09.007

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  124 in total

1.  Timosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in mice.

Authors:  Qi Zhang; Fei Guo; Zhi-wen Fu; Bing Zhang; Cheng-gang Huang; Yang Li
Journal:  Acta Pharmacol Sin       Date:  2015-12-21       Impact factor: 6.150

Review 2.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

3.  NMDA receptor antagonists: tools in neuroscience with promise for treating CNS pathologies.

Authors:  Georg Köhr
Journal:  J Physiol       Date:  2007-03-01       Impact factor: 5.182

4.  Memantine, an NMDA receptor antagonist, differentially influences Go/No-Go performance and fMRI activity in individuals with and without a family history of alcoholism.

Authors:  S Jamadar; E E DeVito; R E Jiantonio; S A Meda; M C Stevens; M N Potenza; J H Krystal; G D Pearlson
Journal:  Psychopharmacology (Berl)       Date:  2012-02-04       Impact factor: 4.530

5.  Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain.

Authors:  Shao-Rui Chen; Gary Samoriski; Hui-Lin Pan
Journal:  Neuropharmacology       Date:  2009-05-05       Impact factor: 5.250

6.  Polysaccharides from wolfberry antagonizes glutamate excitotoxicity in rat cortical neurons.

Authors:  Yuen-Shan Ho; Man-Shan Yu; Suet-Yi Yik; Kwok-Fai So; Wai-Hung Yuen; Raymond Chuen-Chung Chang
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

Review 7.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

Review 8.  Invasive and non-invasive therapies for Alzheimer's disease and other amyloidosis.

Authors:  Gaurav Pandey; Vibin Ramakrishnan
Journal:  Biophys Rev       Date:  2020-09-15

9.  Memantine protects cholinergic and glutamatergic septal neurons from Aβ1-40-induced toxicity.

Authors:  L V Colom; M T Castaneda; D Aleman; A Touhami
Journal:  Neurosci Lett       Date:  2013-02-28       Impact factor: 3.046

10.  Key binding interactions for memantine in the NMDA receptor.

Authors:  Walrati Limapichat; Wesley Y Yu; Emma Branigan; Henry A Lester; Dennis A Dougherty
Journal:  ACS Chem Neurosci       Date:  2012-12-07       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.